BRIEF-Pharma Mar gets IDMC's recommendation to continue phase 3 trial with PM1183

* Independent Data Monitoring Committee recommends to continue unchanged Phase 3 trial with PM1183 in patients with platinum-resistant ovarian cancer

8:18am GMT

BRIEF-Novozymes changes organizational structure

* Changes in organizational structure and executive leadership team

8:15am GMT

BRIEF-C-RAD Q4 operating loss widens to SEK 6.1 mln

* Q4 net sales 20.1 million Swedish crowns ($2.37 million) versus 18.6 million crowns year ago

7:43am GMT

BRIEF-Oasmia submitted marketing authorization application to EMA for Apealea

* Oasmia has submitted a marketing authorization application to the european medicines agency for its lead cancer product apealea Source text for Eikon: Further company coverage:

7:35am GMT

BRIEF-Biomaxima Jan. 2016 revenue up at 2.1 mln zlotys

* Jan. 2016 revenue 2.1 million zlotys ($531,041) versus 1.7 million zlotys a year ago Source text for Eikon: Further company coverage: ($1 = 3.9545 zlotys) (Gdynia Newsroom)

7:13am GMT
GlaxoSmithKline PLC 1,388.00p -0.93%
AstraZeneca PLC 4,047.50p -1.51%
Smith & Nephew PLC 1,060.00p -3.02%


  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.